Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.34 |
| ▸ | RAB9A | P51151 | 5/20 | 0.34 |
| ▸ | IL2 | P60568 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 2/20 | 0.31 |
| ▸ | WNT3A | P56704 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14360793 | 0.88 | NPC1 (0.34) | NPC1RAB9AIL2ABCB1ABCC1 | |
| SCHEMBL14360759 | 0.84 | LMNA (0.39) | NPC1RAB9ALMNAPOLB | |
| SCHEMBL14361064 | 0.84 | NPC1 (0.38) | NPC1RAB9AIL2ABCB1ABCC1 | |
| SCHEMBL13640688 | 0.83 | IL2 (0.42) | NPC1RAB9AIL2ABCB1ABCC1 | |
| SCHEMBL5030853 | 0.82 | IL2 (0.50) | NPC1RAB9AIL2KMT2AKDM4E | |
| SCHEMBL5030830 | 0.82 | IL2 (0.42) | NPC1RAB9AIL2ABCB1ABCC1 | |
| SCHEMBL5436399 | 0.81 | ABCB1 (0.39) | NPC1RAB9AIL2ABCB1ABCC1 | |
| SCHEMBL5027253 | 0.80 | IL2 (0.45) | NPC1RAB9AIL2ABCB1ABCC1 | |
| SCHEMBL5030860 | 0.80 | IL2 (0.48) | NPC1RAB9AIL2KMT2AABL1 | |
| SCHEMBL5029752 | 0.80 | IL2 (0.41) | NPC1RAB9AIL2ABCB1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | NLRP3, CCR1, NLRP1 | NPC1 636/4885RAB9A 2515/4885IL2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.